Published in J Natl Compr Canc Netw on August 01, 2011
The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol (2013) 1.06
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med (2014) 1.03
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract (2012) 0.93
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice. Support Care Cancer (2013) 0.83
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer (2014) 0.81
A way forward on the medically appropriate use of white cell growth factors. J Clin Oncol (2012) 0.78
Myeloid toxicity of cancer treatment. J Adv Pract Oncol (2012) 0.78
Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs (2015) 0.77
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr (2012) 0.76
Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer. Int J Clin Oncol (2014) 0.76
Supportive therapy in medical therapy of head and neck tumors. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.75
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol (2008) 6.90
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies. Cell (2012) 4.37
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med (2006) 4.07
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood (2007) 3.73
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol (2006) 2.92
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood (2012) 2.77
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol (2005) 2.75
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer (2008) 2.50
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol (2006) 2.48
Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood (2008) 2.47
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol (2012) 2.23
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy (2013) 2.16
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol (2002) 2.15
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother (2002) 2.12
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Mutations in the chromatin-associated protein ATRX. Hum Mutat (2008) 2.12
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Thyroid carcinoma. J Natl Compr Canc Netw (2010) 2.02
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood (2010) 2.01
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol (2009) 1.92
Leukocytoreduction for acute leukemia. Ther Apher (2002) 1.88
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw (2006) 1.88
NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Williston Park) (2000) 1.88
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.82
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol (2005) 1.82
Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82
Distress management. Clinical practice guidelines. J Natl Compr Canc Netw (2003) 1.80
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant (2008) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood (2011) 1.73
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood (2014) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. Oncology (2005) 1.57